Oncology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

Fairfield Market Research forecasts robust growth for the global oncology drugs market, estimating a market value of US$ 210 billion in 2024 and projecting it to expand at a compound annual growth rate (CAGR) of 7% to reach US$ 340 billion by the end of 2031.

Market Overview

The oncology drugs market is witnessing a notable surge, driven by the increasing prevalence of cancer globally. As a critical component of the pharmaceutical industry, oncology drugs accounted for a substantial revenue share of the global pharmaceutical drug formulation market. The market's growth trajectory is supported by robust investments in cancer research and the development of innovative therapies.

Sales Analysis and Market Predictions

The oncology drugs market recorded a remarkable growth rate, with a historic CAGR that underscores the sector's dynamic expansion. The volume of clinical trial activities, investment in therapeutics, and the number of therapies in clinical development have all contributed to this growth. Additionally, the introduction of novel active substances has further propelled the market.

Regional Insights

United States: The U.S. remains a lucrative market for oncology drug manufacturers, with a significant share of the North American market. The approval and release of new oncology treatments, coupled with favorable R&D activities and technological advancements in cancer diagnosis and treatment, are key factors driving market growth in the region.

Germany: Germany is a strong player in the European oncology drugs market, driven by the rising prevalence of cancer and substantial investments in R&D. Supportive government policies and the high cost of cancer treatments have also contributed to the market's expansion in Germany.

China: Emerging as a prominent market, China holds a significant share of the East Asian oncology drugs market. The country's robust government investments in R&D and the increasing cancer incidence are major factors propelling market growth. Manufacturers are expanding their production capacities to meet the growing demand for cancer treatments.

Market Drivers

Increase in Funding for Cancer Research: The oncology drugs market is benefiting from increased investments in anti-cancer medications and financing for cancer research. Governments, private industry, and organizations are the primary sources of R&D funding, leading to greater business opportunities in the market.

Innovation in Cancer Treatment: The market is experiencing tremendous growth prospects due to the increased focus on the research and development of treatments and therapies for various cancers, including lung, colorectal, multiple myeloma, and prostate cancer. Partnerships between major pharmaceutical players and funding initiatives are fostering market expansion.

Market Challenges

Unavailability of Cancer Drugs in Underdeveloped Regions: A significant challenge limiting the growth of the oncology drugs market is the lack of availability of major anti-cancer drugs in underdeveloped and developing nations. Factors such as regulatory hurdles, delays in authorization, and financial and logistical challenges contribute to this issue.

High Cost and Limited Access: The high cost of cancer medications and limited coverage provided by public insurance programs are additional barriers to the access and usage of cancer drugs. This is particularly pronounced in low-middle-income countries, where a substantial portion of the population does not have access to essential cancer medications.

Category-wise Insights

Targeted Therapy: The targeted therapy segment holds a significant share of the oncology drugs market. Advancements in gene therapy and cellular technologies have improved the understanding of cancer at the molecular level, driving the demand for targeted therapies.

Breast Cancer: The breast cancer segment is a major driver of market growth, owing to the rising prevalence of breast cancer globally. Early diagnosis and treatment are key focus areas, contributing to the expansion of this market segment.

Competitive Analysis

GlaxoSmithKline plc.
Astrazeneca
Merck KGaA
Johnson & Johnson
Pfizer, Inc.
Bayer AG
Sanofi S.A.
Boehringer Ingelheim
Bausch Health Companies Inc.
Galderma SA
Novartis AG (Alcon)
Arbor Pharmaceuticals
Perrigo Company Plc.
Allergan
Lupin
Teva pharmaceuticals
Ultragenyx Pharmaceutical Inc
Zydus Cadila Healthcare Ltd.
Glenmark Pharmaceuticals

Key Segments in Oncology Drugs Industry Research

By Drug Class:

Chemotherapy
- oAlkylating Agents
- oAntimetabolites
- oAnti-tumour Antibiotics
- oTopoisomerase Inhibitors
- oMitotic Inhibitors
- oOthers
Targeted Therapy
- oMonoclonal Antibodies
- oSmall molecule Inhibitors
Immunotherapy
- oImmune Checkpoint Inhibitors.
- oCell Therapy and Gene Therapy
- oOncolytic Virus Therapy
- oImmune System Modulators
- oOthers
Hormonal Therapy

By Indication:

Breast Cancer
Lung Cancer
Prostate Cancer
Multiple Myeloma
Colorectal Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Chronic lymphocytic Leukaemia
Melanoma
Others

By Route of Administration:

Oral
Injectable

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Oncology Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Key Promotional Strategies, By Manufacturers
2.4. Disease Epidemiology
2.5. Pipeline Assessment
2.6. Regulatory Landscape
2.7. COVID-19 Impact Analysis
2.8. Economic Overview
- 2.8.1. World Economic Projections
2.9. PESTLE Analysis

3. Global Oncology Drugs Market Outlook, 2019 - 2031

3.1. Global Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Chemotherapy
    - 3.1.1.1.1. Alkylating Agents
    - 3.1.1.1.2. Antimetabolites
    - 3.1.1.1.3. Anti-tumour Antibiotics
    - 3.1.1.1.4. Topoisomerase Inhibitors
    - 3.1.1.1.5. Mitotic Inhibitors
    - 3.1.1.1.6. Others
  - 3.1.1.2. Targeted Therapy
    - 3.1.1.2.1. Monoclonal Antibodies
    - 3.1.1.2.2. Small molecule Inhibitors
  - 3.1.1.3. Immunotherapy
    - 3.1.1.3.1. Immune Checkpoint Inhibitors.
    - 3.1.1.3.2. Cell Therapy and Gene Therapy
    - 3.1.1.3.3. Oncolytic Virus Therapy
    - 3.1.1.3.4. Immune System Modulators
    - 3.1.1.3.5. Others
  - 3.1.1.4. Hormonal Therapy
3.2. Global Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Breast Cancer
  - 3.2.1.2. Lung Cancer
  - 3.2.1.3. Prostate Cancer
  - 3.2.1.4. Multiple Myeloma
  - 3.2.1.5. Colorectal Cancer
  - 3.2.1.6. Non-Hodgkin's Lymphoma
  - 3.2.1.7. Kidney Cancer
  - 3.2.1.8. Chronic lymphocytic Leukaemia
  - 3.2.1.9. Melanoma
  - 3.2.1.10. Others
3.3. Global Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Oral
  - 3.3.1.2. Injectable
3.4. Global Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Hospital Pharmacies
  - 3.4.1.2. Retail Pharmacies
  - 3.4.1.3. Others
3.5. Global Oncology Drugs Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa

4. North America Oncology Drugs Market Outlook, 2019 - 2031

4.1. North America Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Chemotherapy
    - 4.1.1.1.1. Alkylating Agents
    - 4.1.1.1.2. Antimetabolites
    - 4.1.1.1.3. Anti-tumour Antibiotics
    - 4.1.1.1.4. Topoisomerase Inhibitors
    - 4.1.1.1.5. Mitotic Inhibitors
    - 4.1.1.1.6. Others
  - 4.1.1.2. Targeted Therapy
    - 4.1.1.2.1. Monoclonal Antibodies
    - 4.1.1.2.2. Small molecule Inhibitors
  - 4.1.1.3. Immunotherapy
    - 4.1.1.3.1. Immune Checkpoint Inhibitors.
    - 4.1.1.3.2. Cell Therapy and Gene Therapy
    - 4.1.1.3.3. Oncolytic Virus Therapy
    - 4.1.1.3.4. Immune System Modulators
    - 4.1.1.3.5. Others
  - 4.1.1.4. Hormonal Therapy
4.2. North America Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Breast Cancer
  - 4.2.1.2. Lung Cancer
  - 4.2.1.3. Prostate Cancer
  - 4.2.1.4. Multiple Myeloma
  - 4.2.1.5. Colorectal Cancer
  - 4.2.1.6. Non-Hodgkin's Lymphoma
  - 4.2.1.7. Kidney Cancer
  - 4.2.1.8. Chronic lymphocytic Leukaemia
  - 4.2.1.9. Melanoma
  - 4.2.1.10. Others
4.3. North America Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Oral
  - 4.3.1.2. Injectable
4.4. North America Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Hospital Pharmacies
  - 4.4.1.2. Retail Pharmacies
  - 4.4.1.3. Others
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S. Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 4.5.1.2. U.S. Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 4.5.1.3. U.S. Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 4.5.1.4. U.S. Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 4.5.1.5. Canada Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 4.5.1.6. Canada Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 4.5.1.7. Canada Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 4.5.1.8. Canada Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Oncology Drugs Market Outlook, 2019 - 2031

5.1. Europe Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Chemotherapy
    - 5.1.1.1.1. Alkylating Agents
    - 5.1.1.1.2. Antimetabolites
    - 5.1.1.1.3. Anti-tumour Antibiotics
    - 5.1.1.1.4. Topoisomerase Inhibitors
    - 5.1.1.1.5. Mitotic Inhibitors
    - 5.1.1.1.6. Others
  - 5.1.1.2. Targeted Therapy
    - 5.1.1.2.1. Monoclonal Antibodies
    - 5.1.1.2.2. Small molecule Inhibitors
  - 5.1.1.3. Immunotherapy
    - 5.1.1.3.1. Immune Checkpoint Inhibitors.
    - 5.1.1.3.2. Cell Therapy and Gene Therapy
    - 5.1.1.3.3. Oncolytic Virus Therapy
    - 5.1.1.3.4. Immune System Modulators
    - 5.1.1.3.5. Others
  - 5.1.1.4. Hormonal Therapy
5.2. Europe Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Breast Cancer
  - 5.2.1.2. Lung Cancer
  - 5.2.1.3. Prostate Cancer
  - 5.2.1.4. Multiple Myeloma
  - 5.2.1.5. Colorectal Cancer
  - 5.2.1.6. Non-Hodgkin's Lymphoma
  - 5.2.1.7. Kidney Cancer
  - 5.2.1.8. Chronic lymphocytic Leukaemia
  - 5.2.1.9. Melanoma
  - 5.2.1.10. Others
5.3. Europe Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Oral
  - 5.3.1.2. Injectable
5.4. Europe Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Hospital Pharmacies
  - 5.4.1.2. Retail Pharmacies
  - 5.4.1.3. Others
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 5.5.1.2. Germany Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.5.1.3. Germany Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 5.5.1.4. Germany Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.5.1.5. U.K. Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 5.5.1.6. U.K. Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.5.1.7. U.K. Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 5.5.1.8. U.K. Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.5.1.9. France Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 5.5.1.10. France Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.5.1.11. France Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 5.5.1.12. France Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.5.1.13. Italy Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 5.5.1.14. Italy Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.5.1.15. Italy Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 5.5.1.16. Italy Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.5.1.17. Turkey Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 5.5.1.18. Turkey Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.5.1.19. Turkey Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 5.5.1.20. Turkey Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.5.1.21. Russia Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 5.5.1.22. Russia Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.5.1.23. Russia Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 5.5.1.24. Russia Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.5.1.25. Rest of Europe Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 5.5.1.26. Rest of Europe Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.5.1.27. Rest of Europe Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 5.5.1.28. Rest of Europe Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Oncology Drugs Market Outlook, 2019 - 2031

6.1. Asia Pacific Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Chemotherapy
    - 6.1.1.1.1. Alkylating Agents
    - 6.1.1.1.2. Antimetabolites
    - 6.1.1.1.3. Anti-tumour Antibiotics
    - 6.1.1.1.4. Topoisomerase Inhibitors
    - 6.1.1.1.5. Mitotic Inhibitors
    - 6.1.1.1.6. Others
  - 6.1.1.2. Targeted Therapy
    - 6.1.1.2.1. Monoclonal Antibodies
    - 6.1.1.2.2. Small molecule Inhibitors
  - 6.1.1.3. Immunotherapy
    - 6.1.1.3.1. Immune Checkpoint Inhibitors.
    - 6.1.1.3.2. Cell Therapy and Gene Therapy
    - 6.1.1.3.3. Oncolytic Virus Therapy
    - 6.1.1.3.4. Immune System Modulators
    - 6.1.1.3.5. Others
  - 6.1.1.4. Hormonal Therapy
6.2. Asia Pacific Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Breast Cancer
  - 6.2.1.2. Lung Cancer
  - 6.2.1.3. Prostate Cancer
  - 6.2.1.4. Multiple Myeloma
  - 6.2.1.5. Colorectal Cancer
  - 6.2.1.6. Non-Hodgkin's Lymphoma
  - 6.2.1.7. Kidney Cancer
  - 6.2.1.8. Chronic lymphocytic Leukaemia
  - 6.2.1.9. Melanoma
  - 6.2.1.10. Others
6.3. Asia Pacific Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Oral
  - 6.3.1.2. Injectable
6.4. Asia Pacific Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Hospital Pharmacies
  - 6.4.1.2. Retail Pharmacies
  - 6.4.1.3. Others
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. China Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 6.5.1.2. China Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.5.1.3. China Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 6.5.1.4. China Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.5.1.5. Japan Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 6.5.1.6. Japan Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.5.1.7. Japan Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 6.5.1.8. Japan Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.5.1.9. South Korea Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 6.5.1.10. South Korea Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.5.1.11. South Korea Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 6.5.1.12. South Korea Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.5.1.13. India Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 6.5.1.14. India Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.5.1.15. India Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 6.5.1.16. India Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.5.1.17. Southeast Asia Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 6.5.1.18. Southeast Asia Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.5.1.19. Southeast Asia Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 6.5.1.20. Southeast Asia Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.5.1.21. Rest of Asia Pacific Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 6.5.1.22. Rest of Asia Pacific Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.5.1.23. Rest of Asia Pacific Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 6.5.1.24. Rest of Asia Pacific Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Oncology Drugs Market Outlook, 2019 - 2031

7.1. Latin America Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Chemotherapy
    - 7.1.1.1.1. Alkylating Agents
    - 7.1.1.1.2. Antimetabolites
    - 7.1.1.1.3. Anti-tumour Antibiotics
    - 7.1.1.1.4. Topoisomerase Inhibitors
    - 7.1.1.1.5. Mitotic Inhibitors
    - 7.1.1.1.6. Others
  - 7.1.1.2. Targeted Therapy
    - 7.1.1.2.1. Monoclonal Antibodies
    - 7.1.1.2.2. Small molecule Inhibitors
  - 7.1.1.3. Immunotherapy
    - 7.1.1.3.1. Immune Checkpoint Inhibitors.
    - 7.1.1.3.2. Cell Therapy and Gene Therapy
    - 7.1.1.3.3. Oncolytic Virus Therapy
    - 7.1.1.3.4. Immune System Modulators
    - 7.1.1.3.5. Others
  - 7.1.1.4. Hormonal Therapy
7.2. Latin America Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Breast Cancer
  - 7.2.1.2. Lung Cancer
  - 7.2.1.3. Prostate Cancer
  - 7.2.1.4. Multiple Myeloma
  - 7.2.1.5. Colorectal Cancer
  - 7.2.1.6. Non-Hodgkin's Lymphoma
  - 7.2.1.7. Kidney Cancer
  - 7.2.1.8. Chronic lymphocytic Leukaemia
  - 7.2.1.9. Melanoma
  - 7.2.1.10. Others
7.3. Latin America Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Oral
  - 7.3.1.2. Injectable
7.4. Latin America Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Hospital Pharmacies
  - 7.4.1.2. Retail Pharmacies
  - 7.4.1.3. Others
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 7.5.1.2. Brazil Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 7.5.1.3. Brazil Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 7.5.1.4. Brazil Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 7.5.1.5. Mexico Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 7.5.1.6. Mexico Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 7.5.1.7. Mexico Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 7.5.1.8. Mexico Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 7.5.1.9. Argentina Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 7.5.1.10. Argentina Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 7.5.1.11. Argentina Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 7.5.1.12. Argentina Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 7.5.1.13. Rest of Latin America Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 7.5.1.14. Rest of Latin America Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 7.5.1.15. Rest of Latin America Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 7.5.1.16. Rest of Latin America Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Oncology Drugs Market Outlook, 2019 - 2031

8.1. Middle East & Africa Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Chemotherapy
    - 8.1.1.1.1. Alkylating Agents
    - 8.1.1.1.2. Antimetabolites
    - 8.1.1.1.3. Anti-tumour Antibiotics
    - 8.1.1.1.4. Topoisomerase Inhibitors
    - 8.1.1.1.5. Mitotic Inhibitors
    - 8.1.1.1.6. Others
  - 8.1.1.2. Targeted Therapy
    - 8.1.1.2.1. Monoclonal Antibodies
    - 8.1.1.2.2. Small molecule Inhibitors
  - 8.1.1.3. Immunotherapy
    - 8.1.1.3.1. Immune Checkpoint Inhibitors.
    - 8.1.1.3.2. Cell Therapy and Gene Therapy
    - 8.1.1.3.3. Oncolytic Virus Therapy
    - 8.1.1.3.4. Immune System Modulators
    - 8.1.1.3.5. Others
  - 8.1.1.4. Hormonal Therapy
8.2. Middle East & Africa Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Breast Cancer
  - 8.2.1.2. Lung Cancer
  - 8.2.1.3. Prostate Cancer
  - 8.2.1.4. Multiple Myeloma
  - 8.2.1.5. Colorectal Cancer
  - 8.2.1.6. Non-Hodgkin's Lymphoma
  - 8.2.1.7. Kidney Cancer
  - 8.2.1.8. Chronic lymphocytic Leukaemia
  - 8.2.1.9. Melanoma
  - 8.2.1.10. Others
8.3. Middle East & Africa Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Oral
  - 8.3.1.2. Injectable
8.4. Middle East & Africa Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Hospital Pharmacies
  - 8.4.1.2. Retail Pharmacies
  - 8.4.1.3. Others
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 8.5.1.2. GCC Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.5.1.3. GCC Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 8.5.1.4. GCC Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 8.5.1.5. South Africa Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 8.5.1.6. South Africa Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.5.1.7. South Africa Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 8.5.1.8. South Africa Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 8.5.1.9. Egypt Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 8.5.1.10. Egypt Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.5.1.11. Egypt Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 8.5.1.12. Egypt Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 8.5.1.13. Nigeria Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 8.5.1.14. Nigeria Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.5.1.15. Nigeria Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 8.5.1.16. Nigeria Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 8.5.1.17. Rest of Middle East & Africa Oncology Drugs Market by Drug Class, Value (US$ Bn), 2019 - 2031
  - 8.5.1.18. Rest of Middle East & Africa Oncology Drugs Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.5.1.19. Rest of Middle East & Africa Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2019 - 2031
  - 8.5.1.20. Rest of Middle East & Africa Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Company Market Share Analysis, 2023
9.2. Competitive Dashboard
9.3. Company Profiles
- 9.3.1. GlaxoSmithKline
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Product Portfolio
  - 9.3.1.3. Financial Overview0020
  - 9.3.1.4. Business Strategies and Development
- 9.3.2. AstraZeneca plc
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Product Portfolio
  - 9.3.2.3. Financial Overview
  - 9.3.2.4. Business Strategies and Development
- 9.3.3. AbbVie
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Product Portfolio
  - 9.3.3.3. Financial Overview
  - 9.3.3.4. Business Strategies and Development
- 9.3.4. Pfizer Inc.
  - 9.3.4.1. Company Overview
  - 9.3.4.2. Product Portfolio
  - 9.3.4.3. Financial Overview
  - 9.3.4.4. Business Strategies and Development
- 9.3.5. Amgen Inc.
  - 9.3.5.1. Company Overview
  - 9.3.5.2. Product Portfolio
  - 9.3.5.3. Financial Overview
  - 9.3.5.4. Business Strategies and Development
- 9.3.6. Gilead Sciences, Inc.
  - 9.3.6.1. Company Overview
  - 9.3.6.2. Product Portfolio
  - 9.3.6.3. Financial Overview
  - 9.3.6.4. Business Strategies and Development
- 9.3.7. F. Hoffmann-La Roche Ltd
  - 9.3.7.1. Company Overview
  - 9.3.7.2. Product Portfolio
  - 9.3.7.3. Financial Overview
  - 9.3.7.4. Business Strategies and Development
- 9.3.8. Bristol-Myers Squibb Company (Celgene Corp)
  - 9.3.8.1. Company Overview
  - 9.3.8.2. Product Portfolio
  - 9.3.8.3. Financial Overview
  - 9.3.8.4. Business Strategies and Development
- 9.3.9. Novartis AG
  - 9.3.9.1. Company Overview
  - 9.3.9.2. Product Portfolio
  - 9.3.9.3. Financial Overview
  - 9.3.9.4. Business Strategies and Development
- 9.3.10. Johnson & Johnson
  - 9.3.10.1. Company Overview
  - 9.3.10.2. Product Portfolio
  - 9.3.10.3. Financial Overview
  - 9.3.10.4. Business Strategies and Development
- 9.3.11. Merck & Co.
  - 9.3.11.1. Company Overview
  - 9.3.11.2. Product Portfolio
  - 9.3.11.3. Financial Overview
  - 9.3.11.4. Business Strategies and Development
- 9.3.12. Eli Lilly and Company
  - 9.3.12.1. Company Overview
  - 9.3.12.2. Product Portfolio
  - 9.3.12.3. Financial Overview
  - 9.3.12.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations